Cargando…
Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428767/ https://www.ncbi.nlm.nih.gov/pubmed/32811685 http://dx.doi.org/10.1016/j.drugpo.2020.102905 |
| _version_ | 1783571149817380864 |
|---|---|
| author | Davis, Corey S. Samuels, Elizabeth A. |
| author_facet | Davis, Corey S. Samuels, Elizabeth A. |
| author_sort | Davis, Corey S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7428767 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74287672020-08-17 Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 Davis, Corey S. Samuels, Elizabeth A. Int J Drug Policy Editorial Elsevier B.V. 2021-07 2020-08-15 /pmc/articles/PMC7428767/ /pubmed/32811685 http://dx.doi.org/10.1016/j.drugpo.2020.102905 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Editorial Davis, Corey S. Samuels, Elizabeth A. Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 |
| title | Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 |
| title_full | Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 |
| title_fullStr | Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 |
| title_full_unstemmed | Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 |
| title_short | Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19 |
| title_sort | continuing increased access to buprenorphine in the united states via telemedicine after covid-19 |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428767/ https://www.ncbi.nlm.nih.gov/pubmed/32811685 http://dx.doi.org/10.1016/j.drugpo.2020.102905 |
| work_keys_str_mv | AT daviscoreys continuingincreasedaccesstobuprenorphineintheunitedstatesviatelemedicineaftercovid19 AT samuelselizabetha continuingincreasedaccesstobuprenorphineintheunitedstatesviatelemedicineaftercovid19 |